Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

0.8575
+0.02753.31%
Post-market: 0.91200.0545+6.36%19:30 EDT
Volume:113.48K
Turnover:98.73K
Market Cap:22.86M
PE:-3.00
High:0.9000
Open:0.8441
Low:0.8310
Close:0.8300
52wk High:3.40
52wk Low:0.7069
Shares:26.65M
Float Shares:21.83M
Volume Ratio:1.20
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.3933
ROE:-69.86%
ROA:-22.85%
PB:2.22
PE(LYR):-2.18

Loading ...

Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland

GlobeNewswire
·
Jul 28

US FDA Approves Otsuka's Novel ADHD Drug Simtriyo for Market Launch

Deep News
·
Jul 28

Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003

TIPRANKS
·
Jul 22

Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion?

Simply Wall St.
·
Jul 14

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

GlobeNewswire
·
Jul 14

Appeals Court Revives Lawsuits Alleging Tylenol Causes Autism and ADHD

Dow Jones
·
Jul 14

Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating

TIPRANKS
·
Jul 08

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

GlobeNewswire
·
Jul 07

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

GlobeNewswire
·
Jul 06

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves

Simply Wall St.
·
Jul 06

ABVC Biopharma Replaces Auditor Simon & Edward with Kreit & Chiu for 2026 Audit

Reuters
·
Jul 03

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

GlobeNewswire
·
Jul 02

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

GlobeNewswire
·
Jun 29

BlinkLab Says European ADHD Study Completes Participant Recruitment, Shares Fall 3%

MT Newswires Live
·
Jun 26

BlinkLab Nears Final Analysis in European ADHD Study After Completing Data Collection

TIPRANKS
·
Jun 26

Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment

TIPRANKS
·
Jun 23

Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk

TIPRANKS
·
Jun 22

Cingulate Faces FDA Delay But Maintains ADHD Drug Plans

TIPRANKS
·
Jun 02

Cingulate Receives Complete Response Letter from FDA for CTx-1301

GlobeNewswire
·
Jun 02

Collegium Pharma Leans on ADHD to Drive Growth

TIPRANKS
·
May 20